More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

California pension fund CalPERS, the second-largest public purchaser of health benefits in the U.S., announced on Tuesday ...

The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & ...

Novo Nordisk reportedly failed to pay its annual fees to maintain the patent rights in Canada, opening the door to cheaper ...

Clever Culture’s APAS is now on trial with Novo Nordisk, and if it delivers, this one machine could unlock a global pharma ...

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...

Find insight on Novo Nordisk, European drug exports, and more in the latest Market Talks covering Health Care.

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month to end a short-lived partnership to sell its Wegovy weight-loss drug ...

Albertsons CEO Susan Morris said she had to "double-check the numbers" when she saw how much cottage cheese the chain was selling.

Digging Into the Bargain Bin Investing in beaten-down stocks can be a savvy strategy for long-term wealth creation, as it ...

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

Connecticut passed a new law last week in an effort to lower its spending on weight-loss drugs for its state insurance ...